29.01.2019 • News

DuPont Breaks Ground for Dutch Bio-Site

DuPont Breaks Ground for Dutch Bio-Site (c) DuPont
DuPont Breaks Ground for Dutch Bio-Site (c) DuPont

DuPont Industrial Biosciences has broken ground on its new multidisciplinary facility in the Leiden Bio Science Park at Oegstgeest, the Netherlands.

With its new project, the Dow-DuPont offshoot said it will use the tools of modern biotechnology to develop bio-based solutions to make industrial processes more efficient and   its products more sustainable.

The work at Leiden will focus on what DuPont terms “the most pressing societal issues of today,” in particular reducing food waste, reducing the environmental impacts of livestock farming and improving animal health as well as producing renewable fuels and lowering environmental impacts in the textile and laundry industries.

Additionally, the new Dutch facility will double the potential for growth of the current employee base, DuPont said, with the potential to create 100 jobs in research and development, application development, marketing, sales and customer service.

The new 7,250 m2 building, scheduled to be completed in 2020, will also serve as the new EMEA (Europe, Middle East and Africa) headquarters of DuPont Industrial Biosciences.

Calling the “ecosystem” of talent, academia and community in the Leiden Bio Science Park “ideal,“ Simon Herriott, vice president & global business director for Bioactives at DuPont, said work at the new site will help the company’s teams to improve the pace of its biotechnology activities and heighten the speed of its products to market.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read